Date: 2015-03-04
Type of information: Distribution agreement
Compound: TruePrime™
Company: Sygnis (Germany) Funakoshi (Japan)
Therapeutic area: Technology - Services
Type agreement: distribution
Action mechanism: TruePrime™ is the brand name of a novel multiple displacement amplification (MDA) technology. TruePrime™ is based on the combination of the recently discovered DNA primase “TthPrimPol” and the extremely processive and high-fidelity Phi29 polymerase to amplify uniformly total genomic DNA for a multitude of applications including next generation sequencing and single cell analysis. The strand displacement capacity of the Phi29 polymerase allows TthPrimPol to generate new primers on the displaced strands that are extended by Phi29 DNA pol, resulting in exponential isothermal DNA amplification without the need of any synthetic random primers.
Disease:
Details: * On March 4, 2015, Sygnis announced that it has signed an non-exclusive distribution agreement for Sygnis’ TruePrime™ family with Funakoshi. Ltd. for the Japanese market. With this agreement, Sygnis grants Funakoshi the non-exclusive rights to promote, market and sell all existing as well as future products for DNA and RNA amplification from smallest amounts of samples down to single cells for applications such as next generation sequencing (NGS) in Japan.
Financial terms:
Latest news:
